Navigation Links
NW Bio Provides Guidance On Phase III Trial Enrollment Timing: Completion Expected To Be Faster Or More Efficient Than Relevant Comparison Trials
Date:3/7/2013

BETHESDA, Md., March 7, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it expects to complete enrollment in its 312-patient Phase III clinical trial for Glioblastoma multiforme (GBM) brain cancer within a period that is faster or more efficient than relevant comparison trials with immune therapies for the same brain cancer.  The Company anticipates completing enrollment of its Phase III trial by Q1 or early Q2 of next year, and expects to reach its first interim analysis for efficacy by approximately Q3 of this year. 

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

Relevant comparisons include the following (according to information publicly reported on www.clinicaltrials.gov and in company announcements and filings):

  • Celldex Therapeutics (NASDAQ: CLDX) is conducting a Phase III trial with 440 patients, at 164 clinical trial sites worldwide, which began enrolling in November 2011, and appears likely to continue enrolling over at least a 4-year period through the end of 2015, with topline results expected at the end of 2016. 
  • Immunocellular Therapeutics (NYSE MKT: IMUC) is conducting a Phase II trial with 124 patients, which were enrolled over the course of 7 calendar quarters from Q1 2011 through Q3 2012.  (IMUC apparently screened 278 patients, but actually enrolled and treated less than half of them:  only 124 patients were enrolled, in aggregate, and treated in either the treatment arm or the placebo arm of the trial.) 
  • <
    '/>"/>
    SOURCE Northwest Biotherapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Medical Alarm Concepts Provides Investor Update - Signs Deal with Health Care Insurance Provider for Medical Alarms
    2. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
    3. Compass Diversified Holdings Provides Shareholders with 2012 Tax Information
    4. Volcano Corporation Provides Additional Guidance For 2013
    5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
    6. AcelRx Pharmaceuticals Provides Clinical Trial Updates
    7. Masimo Reports Fourth Quarter and Full Year 2012 Financial Results; Provides 2013 Financial Guidance
    8. US Peptides Provides New Article Discussing HGH and Athletic Performance
    9. BioMed Realty Trust Provides Notice of Redemption of 7.375% Series A Cumulative Redeemable Preferred Stock
    10. Genomic Health Announces Year-End 2012 Financial Results, Provides 2013 Financial Outlook
    11. Breakthrough Procedure Provides Relief for Acid Reflux
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
    (Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
    (Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
    Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
    ... Dec. 7, 2010 Graymark Healthcare, Inc. (Nasdaq: ... of substantially all the assets of its ApothecaryRx,s retail ... ApothecaryRx operated 18 pharmacies across five states. ... business of providing comprehensive care for sleep disorders, primarily ...
    ... NEW YORK, Dec. 7, 2010 The NuVal™ ... (ActiveHealth®), a provider of evidence-based health information technology ... to bring new tools online to help ActiveHealth ... http://photos.prnewswire.com/prnh/20100119/NE39897LOGO) Beginning in December, NuVal,s nutrition ...
    Cached Medicine Technology:Graymark Healthcare to Focus on Treatment of Sleep Disorders with Completed Sale of Independent Pharmacy Business Assets to Walgreens 2ActiveHealth Management to Deliver Innovative NuVal™ Nutritional Scoring System Through Health Website 2ActiveHealth Management to Deliver Innovative NuVal™ Nutritional Scoring System Through Health Website 3
    (Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
    (Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
    (Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
    (Date:4/17/2014)... Medicine (BUSM) have discovered that the anti-seizure drug ... The findings, reported in the American Journal ... to more effective treatments for alcoholism. , Excessive ... causes of illness and death in the U.S. ... the productivity of workers and necessitating huge health ...
    (Date:4/17/2014)... YORK (17 April 2014) Population Council scientists and their ... safe, stable, and can prevent the transmission of multiple ... rectum in animals: HIV, herpes simplex virus 2 (HSV-2), ... the first data that the gel is effective against ... efficacy in the vagina against all three viruses of ...
    Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
    ... , , , ... , LOUISVILLE, Ky., July 23 University of Louisville physicians ... Hospital in Louisville, KY, on July 17, 2009. The procedure is part ... treat heart disease. , , ...
    ... SAN DIEGO, July 23 Orexigen Therapeutics, Inc. ... priced an underwritten public offering of 10,000,000 shares of its ... proceeds, after estimated underwriting discounts and commissions and estimated expenses, ... a 30-day option to purchase up to an additional 1,500,000 ...
    ... Ohio, July 23 Estimates place the prevalence of physical ... of the global adult population according to THE ORTHOPAEDIC ... , , "Our sources indicate ... increased 25 percent over the past ten years, and those ...
    ... DENVER, CO, July 23 /PRNewswire-FirstCall/ - Medical International Technology ... is pleased to announce that it has been granted ... per "MIT China" requirements, from the "China Medical City" ... half years. , The operation facility will harbor all ...
    ... , , , ... TELEHOUSE America ( www.telehouse.com ) ... exchanges, and managed IT services, today announced it is offering ... prevention (DLP) consulting services as part of its Manage-E ...
    ... , , , ... Media, LLC., a new media and publishing company, today announced the ... a weekly web digest devoted to covering the ideas, technologies, business ... on opportunities for progress in healthcare, Healthspottr delivers select, forward-thinking content ...
    Cached Medicine News:Health News:Orexigen(R) Therapeutics Prices Public Offering of Common Stock 2Health News:THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT Highlights the Burgeoning Demographics of Orthopaedics and the Continuing Health of the Industry 2Health News:MIT granted an 8,000 square foot operation facility in Taizhou city for a period of 2 and half years 2Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 2Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 3Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 4Health News:Introducing Healthspottr: The New Voice of Healthcare Innovation 2Health News:Introducing Healthspottr: The New Voice of Healthcare Innovation 3
    Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
    ...
    For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
    For the qualitative detection of luteinising Hormone (LH) in urine specimens...
    Medicine Products: